Quarterly report · Q1
2372.TEDINET S100OU1N
Period2022-04-01 → 2022-06-30
Filed2022-08-05
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 34
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥4.8bn | 2022-04-01 → 2022-06-30 | Cons. | Net sales |
| Revenue | ¥15.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥3.4bn | 2021-04-01 → 2021-06-30 | Cons. | Net sales |
| Operating income | ¥1.4bn | 2022-04-01 → 2022-06-30 | Cons. | Operating income |
| Operating income | ¥354m | 2021-04-01 → 2021-06-30 | Cons. | Operating income |
| Ordinary income | ¥1.4bn | 2022-04-01 → 2022-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥2.6bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥439m | 2021-04-01 → 2021-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥1.5bn | 2022-04-01 → 2022-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥440m | 2021-04-01 → 2021-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.1bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.0bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥258m | 2021-04-01 → 2021-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥1.1bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss |
| Net income | ¥255m | 2021-04-01 → 2021-06-30 | Cons. | Profit loss |
| Total assets | ¥28.2bn | at 2022-06-30 | Cons. | Assets |
| Total assets | ¥26.6bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥21.8bn | at 2021-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥17.2bn | at 2022-06-30 | Cons. | Liabilities |
| Total liabilities | ¥16.4bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥11.0bn | at 2022-06-30 | Cons. | Net assets |
| Net assets / equity | ¥10.2bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥8.6bn | at 2021-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥5.9bn | at 2022-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥6.4bn | at 2022-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥88.37 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥162.5 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥21.48 | 2021-04-01 → 2021-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥88.22 | 2022-04-01 → 2022-06-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥162.17 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥21.42 | 2021-04-01 → 2021-06-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 38.9% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.1% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 39.3% | at 2021-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 62
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-06-30 | ¥23m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-06-30 | ¥3m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥19m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-06-30 | −¥45m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-06-30 | −¥357m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-06-30 | −¥357m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-06-30 | −¥364m |
| jpcrp040300-q1r_E05352-000Advanced Medicinal Treatmentreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥385m |
| jpcrp040300-q1r_E05352-000Advanced Medicinal Treatmentreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥374m |
| jpcrp040300-q1r_E05352-000Advanced Medicinal Treatmentreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥10m |
| jpcrp040300-q1r_E05352-000Advanced Medicinal Treatmentreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥42m |
| jpcrp040300-q1r_E05352-000CROreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥1.3bn |
| jpcrp040300-q1r_E05352-000CROreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥1.3bn |
| jpcrp040300-q1r_E05352-000CROreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥75m |
| jpcrp040300-q1r_E05352-000CROreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥61m |
| jpcrp040300-q1r_E05352-000Medical Supportreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥468m |
| jpcrp040300-q1r_E05352-000Medical Supportreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥241m |
| jpcrp040300-q1r_E05352-000Medical Supportreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥226m |
| jpcrp040300-q1r_E05352-000Medical Supportreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥36m |
| jpcrp040300-q1r_E05352-000SMOreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥2.9bn |
| jpcrp040300-q1r_E05352-000SMOreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥2.9bn |
| jpcrp040300-q1r_E05352-000SMOreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥24m |
| jpcrp040300-q1r_E05352-000SMOreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥1.7bn |
| —segment total | revenue | 2022-04-01 → 2022-06-30 | ¥5.1bn |
| —segment total | revenue external | 2022-04-01 → 2022-06-30 | ¥4.8bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥337m |
| —segment total | segment profit | 2022-04-01 → 2022-06-30 | ¥1.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-06-30 | ¥5.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-06-30 | ¥4.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥357m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-06-30 | ¥1.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-04-01 → 2021-06-30 | ¥6m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-04-01 → 2021-06-30 | ¥4m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥2m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-04-01 → 2021-06-30 | −¥60m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-06-30 | −¥217m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-06-30 | −¥217m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-06-30 | −¥303m |
| jpcrp040300-q1r_E05352-000Advanced Medicinal Treatmentreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥166m |
| jpcrp040300-q1r_E05352-000Advanced Medicinal Treatmentreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥164m |
| jpcrp040300-q1r_E05352-000Advanced Medicinal Treatmentreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥1m |
| jpcrp040300-q1r_E05352-000Advanced Medicinal Treatmentreportable segment | segment profit | 2021-04-01 → 2021-06-30 | −¥162m |
| jpcrp040300-q1r_E05352-000CROreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥1.1bn |
| jpcrp040300-q1r_E05352-000CROreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥1.1bn |
| jpcrp040300-q1r_E05352-000CROreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥16m |
| jpcrp040300-q1r_E05352-000CROreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥71m |
| jpcrp040300-q1r_E05352-000Medical Supportreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥390m |
| jpcrp040300-q1r_E05352-000Medical Supportreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥228m |
| jpcrp040300-q1r_E05352-000Medical Supportreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥161m |
| jpcrp040300-q1r_E05352-000Medical Supportreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥21m |
| jpcrp040300-q1r_E05352-000SMOreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥1.9bn |
| jpcrp040300-q1r_E05352-000SMOreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥1.9bn |
| jpcrp040300-q1r_E05352-000SMOreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥35m |
| jpcrp040300-q1r_E05352-000SMOreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥787m |
| —segment total | revenue | 2021-04-01 → 2021-06-30 | ¥3.6bn |
| —segment total | revenue external | 2021-04-01 → 2021-06-30 | ¥3.4bn |
| —segment total | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥215m |
| —segment total | segment profit | 2021-04-01 → 2021-06-30 | ¥717m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-06-30 | ¥3.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-06-30 | ¥3.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥217m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-06-30 | ¥657m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 404
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)監査法人アヴァンティア | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)藤 田 憲 三 | |
| Cpa3 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)金 井 政 直 | |
| Number of submission | FilingDateInstant | 1 | |
| Net sales (5-year summary) | Prior1YTDDuration | 3388000000 | JPY |
| Net sales (5-year summary) | CurrentYTDDuration | 4792000000 | JPY |
| Net sales (5-year summary) | Prior1YearDuration | 15693000000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YTDDuration | 439000000 | JPY |
| Ordinary income loss (5-year summary) | CurrentYTDDuration | 1432000000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration | 2562000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YTDDuration | 258000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | CurrentYTDDuration | 1067000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YearDuration | 1961000000 | JPY |
| Comprehensive income (5-year summary) | Prior1YTDDuration | 110000000 | JPY |
| Comprehensive income (5-year summary) | CurrentYTDDuration | 1140000000 | JPY |
| Comprehensive income (5-year summary) | Prior1YearDuration | 1905000000 | JPY |
| Net assets (5-year summary) | Prior1QuarterInstant | 8591000000 | JPY |
| Net assets (5-year summary) | CurrentQuarterInstant | 10996000000 | JPY |
| Net assets (5-year summary) | Prior1YearInstant | 10162000000 | JPY |
| Total assets (5-year summary) | Prior1QuarterInstant | 21750000000 | JPY |
| Total assets (5-year summary) | CurrentQuarterInstant | 28173000000 | JPY |
| Total assets (5-year summary) | Prior1YearInstant | 26588000000 | JPY |
| Basic earnings loss per share (5-year summary) | Prior1YTDDuration | 21.48 | |
| Basic earnings loss per share (5-year summary) | CurrentYTDDuration | 88.37 | |
| Basic earnings loss per share (5-year summary) | Prior1YearDuration | 162.50 | |
| Diluted earnings per share (5-year summary) | Prior1YTDDuration | 21.42 | |
| Diluted earnings per share (5-year summary) | CurrentYTDDuration | 88.22 | |
| Diluted earnings per share (5-year summary) | Prior1YearDuration | 162.17 | |
| Equity to asset ratio (5-year summary) | Prior1QuarterInstant | 0.393 | |
| Equity to asset ratio (5-year summary) | CurrentQuarterInstant | 0.389 | |
| Equity to asset ratio (5-year summary) | Prior1YearInstant | 0.381 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 12306865 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 12307065 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 12306865 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 12307065 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 230200 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 11913200 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 119132 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | 163265 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant | 12306665 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant | 119132 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant_Row1Member | 230200 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant_Row1Member | 230200 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant_Row1Member | 0.0187 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |